A detailed history of Advisor Group Holdings, Inc. transactions in Macrogenics Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 7,730 shares of MGNX stock, worth $26,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,730
Previous 7,770 0.51%
Holding current value
$26,591
Previous $33,000 24.24%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.0 - $5.55 $120 - $222
-40 Reduced 0.51%
7,730 $25,000
Q2 2024

Aug 13, 2024

BUY
$3.31 - $18.51 $25,718 - $143,822
7,770 New
7,770 $33,000
Q4 2023

Feb 12, 2024

SELL
$4.48 - $10.11 $1,576 - $3,558
-352 Reduced 87.56%
50 $0
Q3 2023

Nov 13, 2023

BUY
$4.48 - $6.19 $224 - $309
50 Added 14.2%
402 $1,000
Q2 2023

Aug 10, 2023

SELL
$4.62 - $7.54 $205,248 - $334,972
-44,426 Reduced 99.21%
352 $1,000
Q1 2023

May 12, 2023

SELL
$4.82 - $7.24 $259,643 - $390,004
-53,868 Reduced 54.61%
44,778 $321,000
Q4 2022

Feb 10, 2023

BUY
$3.34 - $6.98 $327,700 - $684,835
98,114 Added 18442.48%
98,646 $661,000
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $397 - $689
132 Added 33.0%
532 $2,000
Q2 2022

Aug 10, 2022

SELL
$2.25 - $9.99 $855 - $3,796
-380 Reduced 48.72%
400 $2,000
Q1 2022

May 04, 2022

SELL
$8.12 - $16.9 $7,916 - $16,477
-975 Reduced 55.56%
780 $6,000
Q3 2021

Nov 05, 2021

SELL
$19.74 - $28.7 $21,950 - $31,914
-1,112 Reduced 38.79%
1,755 $36,000
Q2 2021

Aug 02, 2021

BUY
$20.49 - $35.63 $819 - $1,425
40 Added 1.41%
2,867 $78,000
Q1 2021

May 13, 2021

BUY
$18.99 - $33.2 $27,820 - $48,638
1,465 Added 107.56%
2,827 $90,000
Q4 2020

Feb 10, 2021

BUY
$19.41 - $26.0 $15,683 - $21,008
808 Added 145.85%
1,362 $31,000
Q2 2020

Aug 14, 2020

SELL
$5.2 - $29.12 $17,399 - $97,435
-3,346 Reduced 85.79%
554 $16,000
Q1 2020

May 18, 2020

BUY
$4.28 - $12.11 $16,692 - $47,229
3,900 New
3,900 $22,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $211M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.